Embecta (NASDAQ:EMBC) Updates FY 2026 Earnings Guidance

Embecta (NASDAQ:EMBC) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 1.800-1.900 for the period, compared to the consensus earnings per share estimate of 1.600. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Weiss Ratings lowered shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, August 3rd. Zacks Research upgraded shares of Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Wall Street Zen cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Mizuho dropped their price target on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, BTIG Research downgraded shares of Embecta from a “buy” rating to a “neutral” rating in a report on Tuesday, May 5th. Three analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $11.00.

Embecta Price Performance

NASDAQ EMBC opened at $4.42 on Friday. The stock has a market capitalization of $262.24 million, a P/E ratio of 2.99 and a beta of 0.81. The firm’s 50-day moving average is $3.34 and its two-hundred day moving average is $6.66. Embecta has a 12 month low of $2.77 and a 12 month high of $15.55.

Embecta (NASDAQ:EMBC) last announced its quarterly earnings results on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.29. The business had revenue of $271.70 million during the quarter, compared to analysts’ expectations of $254.53 million. Embecta had a net margin of 10.73% and a negative return on equity of 23.96%. The business’s revenue for the quarter was down 8.1% on a year-over-year basis. During the same period last year, the business earned $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. As a group, analysts anticipate that Embecta will post 1.85 EPS for the current year.

Embecta Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Thursday, August 27th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.9%. The ex-dividend date is Thursday, August 27th. Embecta’s dividend payout ratio (DPR) is 2.11%.

More Embecta News

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates: Embecta reported adjusted EPS of $0.56, exceeding the $0.27 consensus estimate, while revenue of $271.7 million topped expectations of $254.5 million. Embecta Q3 earnings report
• Positive Sentiment: Full-year EPS outlook raised: Management provided fiscal 2026 EPS guidance of $1.80–$1.90, above the $1.60 analyst consensus, signaling stronger expected profitability despite business pressures. Embecta fiscal 2026 results
• Positive Sentiment: Dividend maintained: Embecta declared a quarterly cash dividend of $0.01 per share, providing a modest continuing shareholder return. Embecta dividend announcement
• Neutral Sentiment: Strategic diversification: Embecta reiterated its plan to expand beyond insulin delivery into a broader medical-supplies business. The strategy could create longer-term growth opportunities, but the release provided limited detail on execution or near-term returns. Embecta company announcement
• Negative Sentiment: Sales remain under pressure: Quarterly revenue fell 8.1% year over year to $271.7 million, and EPS declined from $1.12 in the comparable period. This highlights ongoing weakness in Embecta’s core operations even with the earnings beat. Embecta earnings details
• Negative Sentiment: Securities-fraud lawsuit adds risk: Multiple law firms publicized a class action alleging Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business. The August 17 lead-plaintiff deadline increases visibility around potential legal costs, damages and reputational risk. Embecta securities-fraud lawsuit notice

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of EMBC. Brooklyn Investment Group boosted its position in shares of Embecta by 5.9% during the fourth quarter. Brooklyn Investment Group now owns 19,736 shares of the company’s stock worth $234,000 after buying an additional 1,098 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Embecta by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company’s stock valued at $209,000 after buying an additional 1,110 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Embecta by 2.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after acquiring an additional 1,159 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Embecta by 1.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,271 shares of the company’s stock worth $1,785,000 after acquiring an additional 1,520 shares in the last quarter. Finally, Larson Financial Group LLC boosted its holdings in Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after acquiring an additional 1,574 shares during the period. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.